Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis

Dominique Bremond-Gignac, Hachemi Nezzar, Paolo Emilio Bianchi, Riadh Messaoud, Sihem Lazreg, Liliana Voinea, Claude Speeg-Schatz, Dahbia Hartani, Thomas Kaercher, Beata Kocyla-Karczmarewicz, Joaquim Murta, Laurent Delval, Didier Renault, Fred́éric Chiambaretta

Research output: Contribution to journalArticle

Abstract

Objective: To determine the efficacy and safety of azithromycin 1.5% eye drops in a paediatric population with purulent bacterial conjunctivitis. Patients and methods: This was a multicentre, international, randomised, investigator-masked study in 286 children with purulent discharge and bulbar conjunctival injection. Patients received either azithromycin 1.5% eye drops (twice daily for 3 days) or tobramycin 0.3% eye drops (every 2 h for 2 days, then four times daily for 5 days). Clinical signs were evaluated on day (D) 0, 3 and 7, and cultures on D0 and D7. The primary variable was the clinical cure (absence of bulbar conjunctival injection and discharge) on D3 in the worse eye for patients with positive cultures on D0. Results: 286 patients (mean age 3.2 years; range 1 day-17 years) were included; 203 had positive cultures on D0. Azithromycin was superior to tobramycin in clinical cure rate on D3 (47.1% vs 28.7%, p=0.013) and was non-inferior to tobramycin on D7 (89.2% vs 78.2%, respectively). Azithromycin treatment eradicated causative pathogens, including resistant species, with a similar resolution rate to tobramycin (89.8% vs 87.2%, respectively). These results were confirmed in a subgroup of patients younger than 24 months old. Conclusions: Azithromycin 1.5% eye drops provided a more rapid clinical cure than tobramycin 0.3% eye drops in the treatment of purulent bacterial conjunctivitis in children, with a more convenient twice-a-day dosing regimen.

Original languageEnglish
Pages (from-to)739-745
Number of pages7
JournalBritish Journal of Ophthalmology
Volume98
Issue number6
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Ophthalmology

Fingerprint Dive into the research topics of 'Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis'. Together they form a unique fingerprint.

  • Cite this

    Bremond-Gignac, D., Nezzar, H., Bianchi, P. E., Messaoud, R., Lazreg, S., Voinea, L., Speeg-Schatz, C., Hartani, D., Kaercher, T., Kocyla-Karczmarewicz, B., Murta, J., Delval, L., Renault, D., & Chiambaretta, F. (2014). Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. British Journal of Ophthalmology, 98(6), 739-745. https://doi.org/10.1136/bjophthalmol-2013-303888